IL267430B2 - Use of anti-sclerostin antibodies to treat scleroderma - Google Patents
Use of anti-sclerostin antibodies to treat sclerodermaInfo
- Publication number
- IL267430B2 IL267430B2 IL267430A IL26743019A IL267430B2 IL 267430 B2 IL267430 B2 IL 267430B2 IL 267430 A IL267430 A IL 267430A IL 26743019 A IL26743019 A IL 26743019A IL 267430 B2 IL267430 B2 IL 267430B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- sclerostin
- antibody
- sclerostin antibody
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437353P | 2016-12-21 | 2016-12-21 | |
| PCT/GB2017/053850 WO2018115880A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL267430A IL267430A (en) | 2019-08-29 |
| IL267430B1 IL267430B1 (en) | 2025-09-01 |
| IL267430B2 true IL267430B2 (en) | 2026-01-01 |
Family
ID=60915566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267430A IL267430B2 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies to treat scleroderma |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20200179509A1 (pl) |
| EP (2) | EP3868780A1 (pl) |
| JP (3) | JP7050335B2 (pl) |
| KR (3) | KR20240113615A (pl) |
| CN (2) | CN117442720A (pl) |
| AU (1) | AU2017381433B2 (pl) |
| BR (1) | BR112019012731A2 (pl) |
| CA (1) | CA3047221A1 (pl) |
| CL (1) | CL2019001749A1 (pl) |
| CY (1) | CY1124238T1 (pl) |
| DK (1) | DK3478719T6 (pl) |
| ES (1) | ES2862922T7 (pl) |
| FI (1) | FI3478719T6 (pl) |
| HR (1) | HRP20210207T4 (pl) |
| HU (1) | HUE053436T2 (pl) |
| IL (1) | IL267430B2 (pl) |
| LT (1) | LT3478719T (pl) |
| MX (1) | MX2019007161A (pl) |
| NZ (1) | NZ754676A (pl) |
| PL (1) | PL3478719T6 (pl) |
| PT (1) | PT3478719T (pl) |
| SI (1) | SI3478719T2 (pl) |
| WO (1) | WO2018115880A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| MX2019007161A (es) * | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| HRP20260414T1 (hr) | 2018-03-30 | 2026-05-08 | Amgen Inc. | C-terminalne varijante protutijela |
| JP7296408B2 (ja) | 2018-06-18 | 2023-06-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 |
| MA55593A (fr) | 2019-04-11 | 2022-02-16 | Janssen Pharmaceutica Nv | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 |
| KR102472582B1 (ko) * | 2020-08-20 | 2022-11-30 | 한림대학교 산학협력단 | 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법 |
| MX2024003828A (es) * | 2021-09-30 | 2024-05-10 | Mereo Biopharma 3 Ltd | Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta. |
| TW202606715A (zh) * | 2024-04-05 | 2026-02-16 | 美商安進公司 | 治療成骨不全之方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047356A1 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions and methods for use for antibodies against sclerostin |
| WO2016092101A1 (en) * | 2014-12-12 | 2016-06-16 | Amgen Inc. | Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP4813660B2 (ja) | 1998-11-27 | 2011-11-09 | ダーウィン ディスカバリー リミテッド | 骨鉱化作用を増加するための組成物および方法 |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| KR101123487B1 (ko) * | 2007-03-20 | 2012-03-23 | 일라이 릴리 앤드 캄파니 | 항?스클레로스틴 항체 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| BR112012026098A2 (pt) * | 2010-04-16 | 2016-11-22 | Novartis Ag | métodos e composições para melhorar a osseointegração de implante. |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US10961305B2 (en) * | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| MX2019007161A (es) * | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
-
2017
- 2017-12-21 MX MX2019007161A patent/MX2019007161A/es unknown
- 2017-12-21 LT LTEP17823190.8T patent/LT3478719T/lt unknown
- 2017-12-21 DK DK17823190.8T patent/DK3478719T6/da active
- 2017-12-21 CN CN202311429543.0A patent/CN117442720A/zh active Pending
- 2017-12-21 US US16/469,915 patent/US20200179509A1/en not_active Abandoned
- 2017-12-21 EP EP21152251.1A patent/EP3868780A1/en active Pending
- 2017-12-21 PL PL17823190.8T patent/PL3478719T6/pl unknown
- 2017-12-21 AU AU2017381433A patent/AU2017381433B2/en active Active
- 2017-12-21 HR HRP20210207TT patent/HRP20210207T4/hr unknown
- 2017-12-21 JP JP2019533586A patent/JP7050335B2/ja active Active
- 2017-12-21 SI SI201730627T patent/SI3478719T2/sl unknown
- 2017-12-21 CN CN201780087087.2A patent/CN110325548B/zh active Active
- 2017-12-21 CA CA3047221A patent/CA3047221A1/en active Pending
- 2017-12-21 KR KR1020247023410A patent/KR20240113615A/ko not_active Ceased
- 2017-12-21 IL IL267430A patent/IL267430B2/en unknown
- 2017-12-21 EP EP17823190.8A patent/EP3478719B3/en active Active
- 2017-12-21 WO PCT/GB2017/053850 patent/WO2018115880A1/en not_active Ceased
- 2017-12-21 BR BR112019012731-3A patent/BR112019012731A2/pt unknown
- 2017-12-21 PT PT178231908T patent/PT3478719T/pt unknown
- 2017-12-21 NZ NZ754676A patent/NZ754676A/en unknown
- 2017-12-21 ES ES17823190T patent/ES2862922T7/es active Active
- 2017-12-21 HU HUE17823190A patent/HUE053436T2/hu unknown
- 2017-12-21 FI FIEP17823190.8T patent/FI3478719T6/fi active
- 2017-12-21 KR KR1020197021162A patent/KR20190096409A/ko not_active Ceased
- 2017-12-21 KR KR1020227011791A patent/KR20220051269A/ko not_active Ceased
-
2019
- 2019-06-21 CL CL2019001749A patent/CL2019001749A1/es unknown
-
2020
- 2020-01-02 US US16/733,144 patent/US20200123242A1/en not_active Abandoned
- 2020-12-30 US US17/138,691 patent/US20210253684A1/en not_active Abandoned
-
2021
- 2021-04-02 CY CY20211100286T patent/CY1124238T1/el unknown
- 2021-12-10 JP JP2021200994A patent/JP2022046529A/ja active Pending
-
2023
- 2023-04-07 US US18/297,280 patent/US20230365669A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/669,337 patent/US20240400666A1/en active Pending
- 2024-10-11 JP JP2024179475A patent/JP2025020150A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047356A1 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions and methods for use for antibodies against sclerostin |
| WO2016092101A1 (en) * | 2014-12-12 | 2016-06-16 | Amgen Inc. | Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen |
Non-Patent Citations (2)
| Title |
|---|
| MACNABB, CLAIRE, D. PATTON, AND J. S. HAYES., SCLEROSTIN ANTIBODY THERAPY FOR THE TREATMENT OF OSTEOPOROSIS: CLINICAL PROSPECTS AND CHALLENGES., 26 May 2016 (2016-05-26) * |
| OMINSKY, MICHAEL S., ET AL., TWO DOSES OF SCLEROSTIN ANTIBODY IN CYNOMOLGUS MONKEYS INCREASES BONE FORMATION, BONE MINERAL DENSITY, AND BONE STRENGTH., 31 December 2010 (2010-12-31) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240400666A1 (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| US11773171B2 (en) | WNT surrogate molecules and uses thereof | |
| JP6353500B2 (ja) | Ｄｋｋ１抗体およびその使用方法 | |
| US20250122273A1 (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| JP6845012B2 (ja) | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 | |
| KR101620771B1 (ko) | Ｉｌ―17 길항제를 사용하는 건선의 치료 방법 | |
| KR102607829B1 (ko) | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 | |
| KR20170045240A (ko) | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 | |
| HK40058082A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| HK40007021A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| HK40007021B (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |